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ToxicologySystematic review (SR) is a rigorous, protocol-driven approach designed to minimise error and bias when
summarising the body of research evidence relevant to a speciﬁc scientiﬁc question. Taking as a comparator the
use of SR in synthesising research in healthcare, we argue that SR methods could also pave the way for a “step
change” in the transparency, objectivity and communication of chemical risk assessments (CRA) in Europe and else-
where.We suggest that current controversies around the safety of certain chemicals are partly due to limitations in
current CRA procedures which have contributed to ambiguity about the health risks posed by these substances.We
present an overview of how SRmethods can be applied to the assessment of risks from chemicals, and indicate how
challenges in adapting SR methods from healthcare research to the CRA context might be overcome. Regarding the
latter, we report the outcomes from a workshop exploring how to increase uptake of SR methods, attended by ex-
perts representing a wide range of ﬁelds related to chemical toxicology, risk analysis and SR. Priorities which were
identiﬁed include: the conduct of CRA-focused prototype SRs; the development of a recognised standard of
reporting and conduct for SRs in toxicology and CRA; and establishing a network to facilitate research, communica-
tion and training in SR methods. We see this paper as a milestone in the creation of a research climate that fosters
communication between experts in CRA and SR and facilitates wider uptake of SR methods into CRA.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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minimising error and bias1 in the aggregation and appraisal of evidence
relevant to answering a research question. SR techniques were initially
developed in the ﬁelds of psychology, social science and health care and
have, since the 1980s, provided a valuable tool for evidence-informed
decision-making across many domains (Lau et al., 2013). In medicine,
SRs have provided a valuable response to the need for consistent, trans-
parent and scientiﬁcally-robust interpretations of the results of increas-
ing numbers of often conﬂicting studies of the efﬁcacy of healthcare
interventions. SRs have taken on an increasingly fundamental role
both in supporting decision-making in healthcare and, by channelling
resources towards questions for which the answers are not yet
known, reducing waste in research (Chalmers and Glasziou, 2009;
Salman et al., 2014). It is now accepted practice in healthcare to use
SRmethods to assess evidence not only for the efﬁcacy of interventions,
but also on diagnostic tests, prognostics and adverse outcomes.
The extension of SR techniques to other ﬁelds is based on a mutual
need across disciplines to make the best use of existing evidence
when making decisions, a move for which momentum has been grow-
ing for several decades. For example, the What Works Clearinghouse
was established in 2002 to apply SR techniques in support of
American educational policy (US Institute of Education Sciences,
2015), and in 2000 the international Campbell Collaboration research
network was convened to undertake and disseminate systematic re-
views on the effects of social interventions in diverse ﬁelds such as
crime and justice, education, international development and social wel-
fare (Campbell Collaboration, 2015). Meta-analysis and SR in ecology
have contributed to evidence-based environmental policy since the
mid-1990s (Stewart, 2010); more recently, the Collaboration for Envi-
ronmental Evidence (CEE) has been established to encourage conduct
of SRs on a wide range of environmental topics (Collaboration for
Environmental Evidence, 2015).
The potential advantages of adapting SRmethodology to the ﬁeld of
chemical risk assessment (CRA) have also been recognised, with multi-
ple research groups and organisations either developing and adopting
(Woodruff and Sutton, 2014; Birnbaum et al., 2013; European Food
Safety Authority, 2010; Rooney et al., 2014; Aiassa et al., 2015) or
recommending (US National Research Council, 2014a, 2014b; US Envi-
ronmental Protection Agency, 2013; Silbergeld and Scherer, 2013; Hoff-
mann and Hartung, 2006; Zoeller et al., 2015) the use of SRmethods for
evaluating the association between health effects and chemical expo-
sures to inform decision-making. There are, however, a number of
recognised challenges in extending SR methods to CRA, many of
which derive from key differences in the evidence base between the
healthcare and toxicological sciences.
SRs in medicine often focus on direct evidence for beneﬁts and ad-
verse effects of healthcare interventions derived from randomised con-
trolled trials (RCTs) in humans. The evidence base for CRA is generally
more complex, with a need to extrapolate from investigations in ani-
mals, in vitro and in silico, and then to synthesise ﬁndings with those
from human studies if available. Furthermore, the human data tend to
come fromobservational studieswith greater andmore varied potential
for bias and confounding than RCTs, and the range of outcomes to be1 It is worth drawing a distinction between three sources of bias in the review process.
There is potential for bias in the conduct of a review (e.g. because of inappropriate
methods for identifying and selecting evidence for inclusion in the review); bias because
the material available for the review is not representative of the evidence base as a whole
(due to selective publication); and bias arising from ﬂaws in the design, conduct, analysis
and reporting of individual studies included in the review that can cause the effect of an
intervention or exposure to be systematically under- or over-estimated. One of the major
functions of SRs is tominimise bias in the conduct of a review and, as far as possible, to en-
sure that potential bias from selective publication and methodological ﬂaws in the evi-
dence are properly taken into account when drawing conclusions in response to a
research question.considered is usually much wider than in the assessment of healthcare
interventions. Thus, when the various types of toxicological research
are combined into a single overall conclusion about the health risks
posed by a chemical exposure, reviewers are challenged with integrat-
ing the results from a broad and heterogeneous evidence base.
In spite of these differences, there is reason for thinking that SR
methods can be applied successfully to CRA. For example, techniques
for aggregating the results of different study types are already addressed
in various frameworks currently in use in toxicology. These include: In-
ternational Agency of Research on Cancer (IARC) Monographs
(International Agency for Research on Cancer, 2006); the Navigation
Guide (Woodruff and Sutton, 2014); and the US Ofﬁce for Health As-
sessment and Translation (OHAT) (Rooney et al., 2014; USNational Tox-
icology Panel, 2015) – though it should be noted that none of these
approaches have yet applied SR methods to the exposure assessment
component of CRA. Heterogeneous sources of evidence are a familiar
challenge in all domains including clinical medicine (Lau et al., 1998),
and SR of observational studies has a crucial role in identifying compli-
cations and side-effects of healthcare interventions (Sterne et al., 2014;
Higgins and Green, 2011). The need for SR of pre-clinical animal trials of
healthcare interventions, in order to better anticipate beneﬁts and
harms to humans, is another area in which methods being developed
and implemented by a number of groups including SYRCLE
(Hooijmans et al., 2012; van Luijk et al., 2014) and CAMARADES
(Macleod et al., 2005; Sena et al., 2014). (Stewart and Schmid, 2015)
argue that research synthesis methods (including systematic review)
are generic and applicable to any domain if appropriately
contextualised.
Given the sometimes controversial outcomes of CRAs and the grow-
ing public and media proﬁle of the risks that chemicals may pose to
humans and the environment, SR is increasingly viewed as a potentially
powerful technique in assessing and communicatinghow likely it is that
a chemical will cause harm. SR methods add transparency, rigour and
objectivity to the process of collecting the most relevant scientiﬁc evi-
dence with which to inform policy discussions and could provide a crit-
ical tool for organising and appraising the evidence on which chemical
policy decisions are based.
Consequently, in November 2014 a group of 35 scientists and re-
searchers from the ﬁelds of medicine, toxicology, epidemiology, envi-
ronmental chemistry, ecology, risk assessment, risk management and
SR participated in a one-day workshop to consider the application of
SR in CRA. The purpose was three-fold:
1. Identify from expert practitioners in risk assessment and SR the ob-
stacles, in terms of practical challenges and knowledge gaps, to
implementing SR methods in CRA;
2. Develop a “roadmap” for overcoming those obstacles and expediting
the implementation of SR methods, where appropriate, by the vari-
ous stakeholders involved in CRA;
3. Establish the foundations of a network to co-ordinate research and
activities relating to the implementation of SR methods in CRA. The
aim would be to support best practise in the application of SR tech-
niques and promote the wider adoption of SR in CRA, both in
Europe and elsewhere.
Participants heard seven presentations about recent developments
in SR methods, their application to the risk assessment process, and
their potential value to policy-makers. There were two break-out ses-
sions in which participants were divided into three facilitated groups,
ﬁrstly to discuss challenges to implementing SR methods in CRA, and
then to suggest ways in which the obstacles could be overcome. These
ideas were discussed in plenary before being summarised, circulated
for comment, and then published in this paper. TheWorkshopwas con-
ducted under the “Chatham House Rule” such that participants were
free to refer to the information presented and discussed, provided
they did not attribute it to identiﬁable individuals or organisations.
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ploring the application of SRmethods to CRA, the various experts' views
on the challenges to implementing SR methods in CRA, and their sug-
gestions for overcoming them. The remaining goals of the meeting are
ongoing work, including the development of the roadmap concept for
publication and the establishment of a network for supporting the use
of SR in CRA.2. The appeal of SR methods in CRA
Chemical risk assessment is amulti-step process leading to a quanti-
tative characterisation of risk, which can then be used to inform the
management of chemical substances so as to ensure that any risks to
human health or the environment are managed optimally. CRAs entail
four fundamental steps: hazard identiﬁcation; hazard characterisation
(often a dose–response assessment); exposure assessment; and risk
characterisation (see Fig. 1). These steps draw on various ﬁelds of scien-
tiﬁc research including environmental chemistry, toxicology
(encompassing in vivo, in vitro, ecotoxicological and in silico methods),
ecotoxicology, human epidemiology, and mathematical modelling.
There are manyways in which errors can occur in the interpretation
of evidence from these varied disciplines, including failure to consider
all relevant data, failure to allow appropriately for the strengths and lim-
itations of individual studies, and over- or underestimating the rele-
vance of experimental models to real-world scenarios (to name a
few).Whether the appraisal of evidence is based on objective processes,
or on subjective expert judgement and opinion, may also be an impor-
tant factor in accurate interpretation of evidence: the assessment pro-
cess always requires input from technical experts, which inevitably
brings an element of subjectivity to the interpretation of the scientiﬁc
evidence. Different experts may have varying degrees of practical and
cognitive access to relevant information, place differing weight on indi-
vidual studies and/or strands of evidence that they review and, when
working in committee, may be more or less inﬂuenced by dominant
personalities. This can result in misleading conclusions in which the po-
tential for health risks is overlooked, underestimated or overstated. Fur-
thermore, if the factors determining their assessment of evidence are
undocumented, when expert opinions are in conﬂict it can be veryFig. 1.Anoverview to the chemical risk assessment (CRA) process, whereby risk is a function of
process, it is the view of the workshop participants that up to this point in time most attention
issues around conducting a systematic review for exposure assessmentwhichwere not discusse
in exposure studies which may necessitate specialised knowledge of analytical/environmentalchallenging to distinguish which opinion is likely to represent the
most valid synthesis of the totality of available evidence.
A recent illustrative example (see Box 1) of when expert scientists
and reputable organisations have come to apparently contradictory
conclusions about the likelihood of a chemical causing harm is the
case of bisphenol-A (BPA). BPA is a monomer used in the manufacture
of the resinous linings of tin cans and other food contact materials
such as polycarbonate drinks bottles. It has been banned from use in
infant-feed bottles across the EU (European Commission, 1/28/2011)
because of “uncertainties concerning the effect of the exposure of in-
fants to Bisphenol A” (European Commission, 5/31/2011b).
The European Food Safety Authority (EFSA) considers that current
levels of exposure to BPA present a low risk of harm to the public
(European Food Safety Authority, 2015a). The French food regulator
ANSES takes a seemingly different stance on the risks to health posed
by BPA (French Agency for Food, Environmental and Occupational
Health, and Safety, 4/7/2014), determining there to be a “potential risk
to the unborn children of exposed pregnant women”. On this basis,
ANSES has proposed classifying BPA as toxic to reproduction in humans
(French Agency for Food, Environmental and Occupational Health, and
Safety, 2013), a proposal which has contributed to the French authori-
ties' decision to implement an outright ban on BPA in all food packaging
materials (France, 12/24/2012). While the ban has been challenged by
some stakeholders as being disproportionate under EU law
(Tošenovský, 2014, 2015; Plastics Europe, 2015), the Danish National
Food Institute has argued that EFSA has overestimated the safe daily ex-
posure to BPA and that some populations are exposed to BPA at levels
higher than can be considered safe (National Food Institute, Denmark,
2015); a view reﬂected in the conclusions of some researchers, e.g.
(Vandenberg et al., 2014) but not others, e.g. (US Food and Drug
Administration, 2014).
The example of BPA illustrates the challenges in reaching consensus
evenwhen interpreting the same evidence base regarding the potential
toxicity of chemical exposures, either in terms of what is known and
what is uncertain about the risks to health posed by BPA, and/or what
response is appropriate to managing those risks and uncertainties. It
also shows how, in the absence of that consensus, there is a danger
that policy on BPA may become disconnected from the evidence base,
either risking harm to health through continued exposure or incurringhazard and exposure.While SRmethods could inprinciple be applied to all steps of the CRA
has been focused on the hazard identiﬁcation and hazard characterisation steps. There are
d at theworkshop, such as the requirement for a verydifferent tool for assessing risk of bias
chemistry.
Box 1. Examples of conﬂicting opinions from scientists and government agencies about the risks to health posed by bisphenol-A at current exposure levels.
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which is in fact sufﬁciently safe. It also suggests that if the reasons for
disagreement about health risks posed by a chemical are not accessible
to various stakeholders in the debate, it then becomes muchmore difﬁ-
cult for regulators to credibly resolve controversies about chemical
safety, potentially undermining their authority in the long term.
This example highlights the potential for differences in the interpre-
tation of evidence when assessing chemical toxicity and the need for a
process that is not only scientiﬁcally robust but also transparent, so
that the reasons for any disagreement can be readily identiﬁed – includ-
ing giving stakeholders greater opportunity to understand when differ-
ences in policy stem from divergent assessments of risk, andwhen they
stem from divergent opinions as to how those risks are bestmanaged. It
also suggests the importance of the following characteristics in risk as-
sessments that are used to inform risk management decisions:
1. Transparency, in that the basis for the conclusions of the risk assess-
ment should be clear (otherwise they may not be trusted and errors
may go undetected).
2. Validity, in that CRAs should be sufﬁciently (though not necessarily
maximally) scientiﬁcally robust in their methodology and accurate
in their estimation of risks and characterisation of attendant uncer-
tainties as to optimise the decisions that must be made in risk
management.
3. Conﬁdence, providing the userwith a clear statement as to the overall
strength of evidence for the conclusions reached and a characterisa-
tion of the utility of the evidence for decision-making (e.g. “appropri-
ate for hazard identiﬁcation but inappropriate for identiﬁcation of a
reference dose”).
4. Utility, in that the output of the risk assessment should be in a form
that is convenient and intelligible to those who will use it (outputs
that are too detailed and complex to validate and readily compre-
hend lead to inefﬁciency and possibly erroneous decisions).
5. Efﬁciency, providing a clear justiﬁcation of the choice of research
question in the context of efﬁciently solving a CRA problem. Re-
sources for CRA are often limited and it is wasteful to expend unnec-
essary effort on aspects of an assessment that will not be critical to
decision-making (although for the purposes of transparency and va-
lidity, the reasons for focusing on a particular outcome or otherwise
restricting the evaluation should be explained).6. Reproducibility, in that the conclusions of the SR process when ap-
plied to the same question and data should ideally produce the
same answer even when undertaken by different individuals (also
described as “consistency”). In practise, different experts may reach
difference conclusions because they will not all make the same
value judgments about the scope, quality and interpretation of evi-
dence. Therefore, the process should be sufﬁciently rigorous that it
is highly likely that scientiﬁc judgement would result in the same
conclusion independent of the experts involved, and as a minimum
the SR process should render transparent the reasons for all
conclusions.
It may be perceived that the value of SR methods lies in their provi-
sion of unequivocal assessments of whether or not a chemical will in-
duce speciﬁc harm to humans and/or wildlife in given circumstances.
In practise, however, this will happen only if the evidence base is sufﬁ-
ciently extensive, there is unanimity in identiﬁcationof theproblemand
in assessment of the quality of the evidence base, and also how the ev-
idence is to be interpreted in answering the review question (without
this, SRs will also produce different results). Often, the consensus and/
or information may be relatively limited; in such circumstances, a SR
will instead clearly state the limitations of the available data and conse-
quent uncertainties. The value here is in the provision of a comprehen-
sive and transparent assessment of what is not known and insight into
the drivers of divergent opinion. From a research perspective, this yields
valuable information about how research limitations and knowledge
gaps contribute to ongoing uncertainty about environmental and health
risks, allowing the subsequent efforts of researchers to be more clearly
focused. From a policy perspective, SRs offer a transparent explanation
as to why there are differences in opinion which can then be communi-
cated to stakeholders.
Overall, SR contributes to achieving consensus not by eliminating
expert judgement, nor by eliminating conﬂicting opinions about
whether a compound should be banned (for example), but by providing
a robust, systematic and transparent framework for reviewing evidence
of risks, such that when there is disagreement, the reasons for it are
clearly visible and the relative merits of differing opinions can be
appraised. In this way, it may help to resolve controversies in the
interpretation of the science which informs the risk management
process.
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3.1. Traditional vs. SR methods
SR methods are often contrasted with “traditional”, non-systematic
narrative approaches to describing what is and is not already known
in relation to a research question. In reality, the distinction between sys-
tematic and narrative review is a crude one, with narrative reviews
encompassing a number of different approaches to reviewing evidence,
from the caricature of one researcher writing about “my ﬁeld, from my
standpoint […] using only my data and my ideas, and citing only my
publications” (Caveman, 2000), to thorough narrative critiques of com-
prehensively identiﬁed evidence relevant to answering an explicitly ar-
ticulated question, as conducted by organisations such as IARC
(International Agency for Research on Cancer, 2006).
Nonetheless, it is worth noting that only relatively recently has it
been recognised that traditional narrative reviews are, to varying de-
grees, vulnerable to a range of methodological shortcomings which
are likely to bias their summarisation of the evidence base (Chalmers
et al., 2002). These include selective rather than comprehensive re-
trieval of evidence relevant to the review topic, inconsistent interpreta-
tion of the impact of methodological shortcomings on the validity of
included studies, and even an absence of clear review objectives or con-
clusions which are drawn directly from the strengths and limitations of
the evidence base (Mulrow, 1987; Mignini and Khan, 2006).
The presence of these shortcomings seriously challenges the reader's
ability to determine the credibility of a review. When there exist multi-
ple competing reviews, each using opaque methods, it becomes almost
impossible to judge their relative merits and therefore to base decisions
on current best available evidence. The consequence is a proliferation of
conﬂicting opinions about best practice that fail to take proper account
of the body of research evidence. In the healthcare sciences, thiswas ini-
tially shown by Antman and colleagues when they found that, in
comparison to recommendations of clinical experts, systematic aggre-
gation of data from existing clinical trials of streptokinase to treat myo-
cardial infarction would have demonstrated beneﬁt some years before
recommendations for its use became commonplace (Antman et al.,
1992). More recently, cumulative meta-analyses have been shown to
be more accurate in summarising current understanding of the size of
effect of awide range of healthcare interventions than researchers plan-
ning new clinical trials who have not used these methods (Clarke et al.,
2014).
A SR is an approach to reviewing evidencewhich speciﬁcally sets out
to avoid these problems, by methodically attempting “to collate all em-
pirical evidence that ﬁts pre-speciﬁed eligibility criteria in order to an-
swer a speciﬁc research question,” using “explicit, systematic methods
that are selected with a view to minimising bias” (Higgins and Green,
2011).
In detail, this amounts to the pre-speciﬁcation of the objective and
methods of the SR in a written protocol, in which the aim of conducting
the review is clearly stated as a structured question (for a SR of the ef-
fects of an intervention or exposure, this can establish a testable hypoth-
esis or quantitative parameter that is to be estimated), along with the
articulation of appropriate methods. The methods speciﬁed should in-
clude the techniques for identifying literature of potential relevance to
the research question, the criteria for inclusion of the studies of actual
relevance to the research question, how the internal validity2 of the2 “Internal validity” is a termused inCochraneCollaboration guidance on conduct of SRs
speciﬁcally intended to supersede the use of terms such as “methodological quality” or
their equivalents, which are considered ambiguous (Higgins and Green, 2011). The inter-
nal validity of a piece of research is appraised in a “risk of bias” assessment. The target of
the risk of bias assessment is the likelihood, magnitude and direction of systematic error
in the size of an observed effect, as caused by ﬂaws in the design, conduct, analysis and
reporting of a study. Throughout this document, we follow Cochrane Collaboration con-
ventions in using “internal validity” as a technical term in place of “methodological
quality”.included studies will be appraised, and the analytical techniques used
for combining the results of the included studies. The purposes of the
protocol are to discourage ad-hoc changes to methodology during the
review processwhichmay introduce bias, to allow any justiﬁablemeth-
odological changes to be tracked, and also to allow peer-review of the
work that it is proposed, to help ensure the utility and validity of its ob-
jectives and methods.
The ﬁnal SR itself consists of a statement of the objective, the search
method, the criteria for including relevant studies for analysis, and the
results of the appraisal of internal validity of the included studies, e.g.
implemented as a “risk of bias” assessment in Cochrane Reviews of
randomised trials (Higgins et al., 2011). The evidence is then synthe-
sised using statistical meta-analytical techniques, narrative methods
or both (depending on the extent to which meta-analysis is possible)
into an overall answer to the research question. An assessment is then
made of the strength of the evidence supporting the answer; in
Cochrane reviews, this typically follows the GRADE methodology
(Atkins et al., 2004), taking into account overall features of the evidence
base including risk of bias across the included studies, publication bias
in the evidence base, external validity or applicability of the evidence
to the population of interest, heterogeneity of the evidence, and the
overall precision of the evidence. This is ﬁnally followed by a concluding
interpretation ofwhat the SR as awhole determines is and is not known
in relation to its objective.
In this, we emphasise the distinction between a SR and a meta-
analysis. Ameta-analysis pools the results of a number of separate stud-
ies in a single statistical analysis andmay be a component of a SR; how-
ever, it does not necessarily incorporate the full set of methodological
features which deﬁne the SR process (e.g. a meta-analysis may or may
not include an assessment of the internal validity of included studies).
While we acknowledge that some researchers use the terms “system-
atic review” and “meta-analysis” interchangeably, we believe the two
approaches should be disambiguated. It is also worth noting that
many reviews employ a combination of narrative and systematic
methods; there were differing opinions among workshop participants
as to the extent towhich it is reasonable to expect all reviews to fully in-
corporate SR methods.
3.2. The current status of SR in environmental health, toxicology and CRA
While the use of SR methodologies is well established in healthcare
to determine the effect of interventions on health outcomes or the accu-
racy of a diagnostic test, application of SR is relatively novel in the ﬁelds
of toxicology and environmental health. Workshop participants heard
how methods for SR of medical interventions have in the United
States been adapted in both academic and federal contexts to the gath-
ering and appraising of evidence for the effects of chemical exposures
on humanhealth: researchers at the University of California have devel-
oped the Navigation Guide (Woodruff and Sutton, 2014), and the US Of-
ﬁce of Health Assessment and Translation (OHAT) at the US National
Toxicology Program has developed the OHAT Framework for systemat-
ically reviewing environmental health research for hazard identiﬁcation
(Rooney et al., 2014).
The two approaches adapt the key elements of SR methods to ques-
tions in environmental health (which is directly relevant to the CRA
process but does not include assessment of dose–response). Features
that the two approaches have in common include: conducting a SR ac-
cording to a pre-speciﬁed protocol; the development of a speciﬁc
research question and use of “PECO” statements (see Box 2) in
systematising review objectives and the methods that will be used to
answer that question; an approach to appraising the internal validity
of included studies adapted from the risk of bias appraisal tool devel-
opedby the Cochrane Collaboration (Higgins et al., 2011); an adaptation
of the GRADE methodology (Atkins et al., 2004) for describing the cer-
tainty or strength of a body of evidence, incorporating risk of bias ele-
ments with other criteria such as for the assessment of relevance or
Box 2. The use of PECO statements in the SR process.
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human and animal research into a statement of conﬁdence about the
hazard which a chemical poses to health.
Other tools are being developed to contribute to the systematic as-
sessment of in vivo and ecotoxicity studieswhich have not been directly
derived from Cochrane Collaboration methods. Presented at the Work-
shop was SciRAP (Science in Risk Assessment and Policy), a system de-
veloped to improve the consistency with which the relevance and
reliability of studies are appraised in the context of conducting a chem-
ical risk assessment for regulatory purposes. It is also intended to reduce
the risk of selection bias in the risk assessment process by providing a
mechanism for including non-standardised study methods yielding po-
tentially valuable data (Beronius et al., 2014; SciRAP, 2014).
There are a number of other initiatives promoting and developing
the use of SRmethodologies in environmental and chemical risk assess-
ment. Participants heard about how the European Food Safety Authority
is integrating SR methods into its assessments of food and feed safety
(European Food Safety Authority, 2015b, 2015c), and about the UK
Joint Water Evidence Group methods for rapid and systematic assess-
ments of evidence (Collins et al., 2014). Other coordinated initiatives in-
clude the Evidence-Based Toxicology Collaboration (Hoffmann and
Hartung, 2006); the Collaboration for Environmental Evidence (Bilotta
et al., 2014a; Land et al., 2015); and the Systematic Review Centre for
Laboratory Animal Experimentation (SYRCLE).
3.3. Overcoming the challenges in implementing SR methods in CRA
Risk assessment for a chemical or group of chemicals is a multi-
faceted process that normally requires consideration of multiple end-
points in relation to a variety of exposure scenarios, integrating evi-
dence from epidemiological studies, bioassays in animals, mechanistic
studies and studies on the distribution and determinants of exposure
by different pathways and routes. In addition to resolving methodolog-
ical issues relating to underdeveloped methods (e.g. how SR methods
can be used as part of dose–response assessment or how they can be ap-
plied to exposure assessment), it is important to consider how SR
should ﬁt into the CRA process. One challenge going forward is to ex-
plore the circumstances in which applying more rigorous SR methods
to assess scientiﬁc evidence would be warranted, which would require
insight into the practicality and cost-effectiveness of applying such
methods in those situations.
In principle, it should be possible to conduct SRs in any aspect of a
CRA. Given the success in employing SR methods to support evidence-
based practice in healthcare, it is intuitive that SRs could address speciﬁc
questions arising within toxicology, human epidemiology and environ-
mental health (e.g. hazard assessment within a CRA) and this view ap-
pears to be gaining momentum within the environmental health
literature. The SR method may also lend itself to answering questions
concerning e.g. the accuracy of the reported physical-chemical proper-
ties of a substance, doses predicted by quantitative exposureassessment, concentrations of a chemical in the environment and
biota, and the derivation of a No Observed Adverse Effect Level
(NOAEL) or Benchmark Dose Lower 95% conﬁdence limit (BMDL).
European Food Safety Authority (2015c) explores these issues in more
detail.
Depending on scope, the resources (time and cost) to undertake an
SR can be considerable. Currently there is a lack of empirical evidence
relating to the resource-effectiveness of SR approaches in CRA and
there was a difference of opinion among workshop participants as to
whether the effort required for conducting a SR tends to be under- or
overestimated. It was suggested that, where effort is likely to be sub-
stantial, efﬁcient use of resources may be achieved by focusing on
high-value questions developed through initial scoping exercises. For
example, a low-dose adverse effect may be evident in animal models
and supported to some extent by human epidemiology and hence a
question may be formulated around this initial evidence; there may be
little point, however, in pursuing a question related to non-
carcinogenic toxicity in wildlife if a substantial part of the literature
points towards that substance being a potential human carcinogen.
There is also growing interest in rapid reviews, when full SR methods
are considered overly onerous (Collins et al., 2014; Schünemann and
Moja, 2015).
The priorities for expediting the adaptation of SR methods to CRA
identiﬁed at the Workshop are as follows:
1. The development of a number of prototype CRA-focused SRs to ex-
plore how readily SR procedures can be integrated into the CRA pro-
cess, to:
a. identify additional methodological challenges in adapting SR
methods to the CRA context and develop techniques to address
them;
b. acquire practical experience in managing resources when
conducting SRs in CRA, including the conduct of scoping exercises
for identifying high-value review questions, the further develop-
ment and/or application of novel “rapid evidence review”methods
(UK Civil Service, 2015), and how SR methods can be integrated
into existing regulatory structures such as REACH (see Box 3)
(European Chemicals Agency (2/26/2015)).
2. Technical development of SR methodologies for CRA purposes, in
particular the further advancement of techniques for appraising
and synthesising mechanistic, toxicological and human epidemio-
logical studies, to include:
a. reﬁning tools for more consistent and scientiﬁcally robust ap-
praisal of the internal validity of individual studies included in a
CRA and the implications for interpretation of their ﬁndings; see
e.g. Bilotta et al. (2014b). This might include further development
and validation of tools such as the SYRCLE methodology for
assessing the internal validity of animal studies (Hooijmans et al.,
2014); for SR of observational studies see e.g. Sterne et al. (2014),
Box 3. The potential utility of SR methods in application to REACH registrations.
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protocols, and the applicability of other assessment methods
such as SciRAP (Beronius et al., 2014);
b. the development of tools for the hazard characterisation and expo-
sure assessment components of the CRA process;
c. the further development of software akin to the Cochrane
Collaboration's Review Manager (Nordic Cochrane Centre, 2014)
and the Systematic Review Data Repository (Ip et al., 2012), and
tools such as DRAGON (ICF International, 2015) and the Health As-
sessment Workspace Collaborative (Rusyn and Shapiro, 2013) to
support extraction, analysis and sharing of data from studies in-
cluded in reviews;
3. The development an empirical evidence base for the different types
of bias that operate in the CRA domain, including their direction
and potential magnitude, and the extent to which any methods
being adopted to address them are appropriate and effective.
4. The development of a recognised “gold standard” for SRs in toxicol-
ogy and risk assessment equivalent to the Cochrane Collaboration
in evidence-based medicine, to address the growing number of pur-
ported SRs of unclear validity which are increasingly prevalent in the
environmental health literature.
5. The creation of a climate of constructive discussion that fosters ad-
vancement of methods whereby chemical risk practitioners, indus-
try, competent authorities, academic researchers and policy makers
can research, discuss and evaluate SR methods and the potential ad-
vantages they can bring.
6. The establishment of a network of scientists and CRA practitioners to
pursue research into and discussion of SR methodologies and facili-
tate their implementation.
7. The implementation of training programmes for risk assessment
practitioners and stakeholders, focusing speciﬁcally on applicationof SR methods to CRA as a complement to current courses which
largely cover SR methods in healthcare.4. Conclusions
While systematic review methods have proven highly inﬂuential in
healthcare, they have yet to make widespread impact on the process
of chemical risk assessment.While there ismuchpromise in the concept
of adapting SR methods to CRA to give deﬁnitive answers to speciﬁed
research questions, or to enable identiﬁcation of the reasons for failure
to resolve debate, a number of challenges to implementing SR methods
in CRAhave been identiﬁed. These include particular concerns about ap-
proaches to assessing bias and confounding in observational studies, the
effort involved in conducting SRs, and the subsequent beneﬁts of
conforming to SR standards. Recent experience from both regulatory
agencies and academics already yields some clear recommendations
which would expedite the wider implementation of SR methods in
CRA, potentially increasing the efﬁciency, transparency and scientiﬁc
robustness of the CRA process.
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